@article{TLCR16551,
author = {Alejandro Navarro and Enriqueta Felip},
title = {Pembrolizumab in advanced pretreated small cell lung cancer patients with PD-L1 expression: data from the KEYNOTE-028 trial: a reason for hope?},
journal = {Translational Lung Cancer Research},
volume = {6},
number = {Suppl 1},
year = {2017},
keywords = {},
abstract = {Small cell lung cancer (SCLC) is an aggressive subtype of lung cancer, representing around 15% of all lung cancer cases. SCLC is characterized by neuroendocrine pathological features, strong association with tobacco exposure, rapid widespread, high mutational rates and no oncogenic drivers (1).},
issn = {2226-4477}, url = {https://tlcr.amegroups.org/article/view/16551}
}